TriSalus Life Sciences, Inc.

Stage 3 · Topping · week 1

As of Oct 22, 2026, TriSalus Life Sciences is in Stage 3, the topping phase, now in its first week (since Oct 16, 2026). It closed at $3.66, 51.2% below its 52-week high and below its 200-day average, which is falling.

$3.66

-0.27% today

$225M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is TLSI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 16w

S2 15w

S4 26w

S4 19w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 1w → S4 16w → S1 7w → S2 15w → S3 6w → S4 26w → S1 8w → S2 9w → S3 13w → S4 10w → S1 5w → S4 2w → S1 1w → S2 10w → S3 4w → S4 19w → S1 7w → S2 4w → S3 1w current

Total tracked: 165 weeks across 20 stage runs.

TLSI among Medical Devices70th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…70	TLSITriSalus Life Sciences, Inc.	Stage 3 · wk 1	34	−26.8%

vs 52W High

-51.2%

$2.52 lo$7.50 hi

51.2% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 1

1w13w26w

Week 1, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-18.1%

200 DMA: $4.47 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.35x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-26.8%

-13.3%

-21.0%

YTD

-40.0%

-28.8%

Scan Membership

Breakout Watch

Latest: 2025-03-06

4 appearances in last 60 days. First seen: 2021-11-19.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 1 · Vol 0.35x

2026-10-21S3

Wk 1 · Vol 0.23x

2026-10-20S3

Wk 1 · Vol 0.36x

2026-10-19S3

Wk 1 · Vol 0.36x

2026-10-16S32→3

Wk 1 · Vol 0.87x

2026-10-15S2

Wk 4 · Vol 0.47x

2026-10-14S2

Wk 4 · Vol 0.64x

2026-10-13S2

Wk 4 · Vol 0.40x

2026-10-12S2

Wk 4 · Vol 0.26x

2026-10-09S2

Wk 4 · Vol 0.66x

2026-10-08S2

Wk 3 · Vol 0.93x

2026-10-07S2

Wk 3 · Vol 0.63x

Moving averages & range

50 DMA

$4.63

200 DMA

$4.47

52W High

$7.50

52W Low

$2.52

5D Low

$3.53

Resistance levels (recent highs)

20d High

$4.39

60d High

$5.74

120d High

$5.74

250d High

$7.50

Next resistance

+19.9%

to 20d High

Dividend Yield

0.00%

P/B 34.2

TriSalus Life Sciences: quick answers

What stage is TriSalus Life Sciences in?

As of Oct 22, 2026, TriSalus Life Sciences (TLSI) is in Stage 3, the topping phase. It entered Stage 3 on Oct 16, 2026 and is in its first week there. What the four stages mean

Is TriSalus Life Sciences in an uptrend?

Its uptrend has stalled. TriSalus Life Sciences is in Stage 3, the topping phase that follows an advance. It trades 18.1% below its 200-day average, which is falling.

How far is TriSalus Life Sciences from its 52-week high?

TriSalus Life Sciences closed at $3.66 on Oct 22, 2026, 51.2% below its 52-week high of $7.50. Its 52-week low is $2.52.

How has TriSalus Life Sciences performed over the past year?

As of Oct 22, 2026, TriSalus Life Sciences is down 28.8% over the past year and down 40.0% so far in 2026.

Which sector and industry is TriSalus Life Sciences in?

TriSalus Life Sciences is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.